CT-95 Trial for Advanced Cancers
Phase 1
70
about 3.8 years
18+
7 sites in CO, IL, MI +4
What this study is about
This trial is testing CT-95, a new drug, in people with advanced cancers that have Mesothelin. The goal is to see if CT-95 is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CT-95
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Determine the MTD or RD of CT-95 [Safety and Tolerability], Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary: Evaluate Overall Survival [Survival], Evaluate Progression-free Survival [Anti-tumor Activity], Evaluate the Area Under the Curve (AUC) [Pharmacokinetics], Evaluate the Maximum Serum Concentration (Cmax) [Pharmacokinetics]
Oncology, Respiratory